Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of the ...

Sage Therapeutics experimental drug to treat postpartum depression showed positive results in a recent mid-stage study, according to Reuters. The drug, called SAGE-547, produced a significant ...

The FDA's approval late Friday made zuranolone the first oral treatment for postpartum depression, a common complication that affects 1 in 8 women during and after pregnancy and hinders their ability ...

Nov 20 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients ...

Sage Therapeutics Axes GC After Drug-Pipeline Failures Force Cost-Cutting Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The third trial failure thios ...

Oct 8 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Following a series of ...